Skip to main content
SpringerLink
Log in

Kein Vorteil einer Erhaltungstherapie mit Afatinib in der adjuvanten Therapie von Kopf-Hals-Tumoren

Afatinib maintenance therapy does not confer any benefit in the adjuvant treatment of head and neck tumors

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Tupchong L, Scott CB, Blitzer PH et al (1991) Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 20(1):21–28

    Article  CAS  PubMed  Google Scholar 

  2. Bernier J, Domenge C, Ozsahin M et al (2004) European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952

    Article  CAS  PubMed  Google Scholar 

  3. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944

    Article  PubMed  Google Scholar 

  4. Racadot S, Thennevet I, Ouldbey Y et al (2023) Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010e02). Eur J Cancer 178:114–127

    Article  CAS  PubMed  Google Scholar 

  5. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  CAS  PubMed  Google Scholar 

  6. Magrini SM, Buglione M, Corvò R et al (2016) Cetuximab and radiotherapy versus Cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. https://doi.org/10.1200/JCO.2015.63.1671

    Article  PubMed  Google Scholar 

  7. Zhang L (2021) Efficacy and safety of afatinib in advanced non-small cell lung cancer with EGFR mutations: a real-world study based meta-analysis. J Clin Oncol 34:427–435

    Google Scholar 

  8. Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Article  CAS  PubMed  Google Scholar 

  9. Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol 29:3044–3060

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MVZ für Strahlentherapie und Radioonkologie, Buchforststraße 14, Köln, Deutschland, 51103

    Alexander Maximilian Ziebolz

  2. Arbeitsgruppe junge DEGRO der Deutschen Gesellschaft für Radioonkologie e.V., Berlin, Deutschland

    Alexander Maximilian Ziebolz

Authors
  1. Alexander Maximilian Ziebolz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Maximilian Ziebolz.

Ethics declarations

Interessenkonflikt

A.M. Ziebolz gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Radacot S, Thennevet I, Ouldbey Y et al (2023) Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010e02). European Journal of Cancer 178:114e127.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ziebolz, A.M. Kein Vorteil einer Erhaltungstherapie mit Afatinib in der adjuvanten Therapie von Kopf-Hals-Tumoren. Strahlenther Onkol 199, 428–429 (2023). https://doi.org/10.1007/s00066-023-02069-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-023-02069-7

Search

Navigation